The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.083%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 24.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Sound Energy falls on Morocco tax notification

Tue, 01st Jun 2021 11:30

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Sareum Holdings PLC, up 17% at 3.04 pence, 12-month range 1.20p-3.38p. The specialist drug development company says it has raised GBP900,000 through a subscription by a "high net worth individual" for 32.1 million new shares at a price of 2.8p per share. Says net proceeds from the Subscription will be used to progress the company's SDC-1801 TYK2/JAK1 inhibitor drug development programmes as well as for working capital purposes.

----------

Springfield Properties PLC, up 14% at 170.30p, 12-month range 105.00p-172.00p. The housebuilder says sales activity in the first half of the year has been sustained throughout the year and is continuing to experience high demand across the business. As a result, expects annual revenue and profit to be ahead of market expectations, reflecting significant year-on-year revenue growth.

----------

M&C Saatchi PLC, up 13% at 144.50p, 12-month range 68.00p-183.79p. The advertising agency says it has seen "stronger than anticipated" trading for year's first four months. As such, it expects annual results to be ahead of expectations.

----------

i3 Energy PLC, up 12% at 8.38p, 12-month range 4.65p-11.00p. The UK and Canada-focused oil & gas company swings to pretax profit in 2020 of GBP10.6 million from GBP10.9 million loss in 2019. It posts revenue of GBP13.0 million, up from nothing the year before.

----------

AIM - LOSERS

----------

Sound Energy PLC, down 15% at 1.48p, 12-month range 1.02p-4.72p. The Moroccan-focused upstream gas company says it has received a notification from Morocco's tax authority related to an audit. Sound says its subsidiary Sound Energy Morocco East has received notification by the Moroccan General Tax Administration of a reassessment in respect of Moroccan taxes related to 2016 to 2018. Sound Energy "entirely refutes" the position of the Moroccan tax authority, saying it is speaking to the government to seek a satisfactory conclusion to the matter. Says local tax committee hearing is on Thursday, but the process can take 12 months.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 May 2018 12:17

Sareum Regains Worldwide Rights To Leukaemia Treatment

LONDON (Alliance News) - Sareum Holdings PLC said on Thursday that it has regained its worldwide rights to a potential treatment for leukaemia and other blood-related cancers.The drug said

Read more
15 Mar 2018 13:55

Sareum Partner Sierra Oncology To Present Positive SRA737 Results

LONDON (Alliance News) - Sareum Holdings PLC said Thursday its development partner Sierra Oncology's SRA737 results have been accepted for presentation at the annual of of

Read more
9 Jan 2017 16:39

Sareum Holdings receives milestone payment

(ShareCast News) - Sareum Holdings, an AIM listed specialist cancer drug discovery and development company, has announced the attainment of a $2m milestone payment as part of the Chk1 license agreement between its co-investment partner the CRT Pioneer Fund and Sierra Oncology, formerly known as ProN

Read more
9 Jan 2017 12:19

Sareum To Receive USD550,000 From Joint Licence Success Payment

Read more
24 Oct 2016 15:02

Sareum reports positive results from TYK2 programme

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced a successful conclusion from its feasibility study into the potential for its TYK2 programme lead molecules to treat T-Cell Acute Lymphoblastic Leukaemia (T-ALL) on Monday. The AIM-traded company said the i

Read more
24 Oct 2016 08:13

Sareum Welcomes Positive Feasibility Results For Leukemia Treatment

Read more
17 Oct 2016 14:16

Sareum Holdings granted patents in Japan and Singapore

(ShareCast News) - Specialist cancer drug discovery and development company Sareum announced on Monday that the Japan and Singapore Patent Offices have issued notifications that patents will be granted for inventions associated with its Aurora+FLT3 kinase inhibitor programme. The AIM-traded firm sai

Read more
27 Sep 2016 11:13

Sareum Holdings Co-Investment Partner Inks Licence Agreement

Read more
3 Aug 2016 14:56

Sareum programme receives patents in Hong Kong and China

(ShareCast News) - Specialist cancer drug discovery and development business Sareum announced on Wednesday that the Chinese Patent Office and the Hong Kong Patents Registry have issued notifications that patents will be granted for inventions associated with the company's Aurora+FLT3 Kinase Inhibito

Read more
23 May 2016 11:06

Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
23 May 2016 11:01

*Sareum Holdings Says Phase I CCT245737 Trials To Open End Of May

Read more
17 May 2016 08:03

Sareum Appoints Silence Therapeutics' Stephen Parker As Chairman

Read more
5 Apr 2016 12:33

Sareum cancer drug candidate gets MHRA trial approval

(ShareCast News) - Sareum Holdings was pressing ahead with one of its cancer drug programmes on Tuesday, having received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the Clinical Trial Applications submitted for CHK1 inhibitor drug candidate CCT245737. The AIM-tra

Read more
5 Apr 2016 09:46

Sareum Holdings Gets Clinical Trial Approval For Cancer Drug Candidate

Read more
24 Mar 2016 12:03

Sareum Raises GBP1.1 Million For Drug Development Programmes (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.